Alginate hydrogels functionalized with β-cyclodextrin as a local paclitaxel delivery system
Line Aanerud Omtvedt1, Kåre Andre Kristiansen1, Wenche Iren Strand1
1NOBIPOL, Department of Biotechnology and Food Science, NTNU Norwegian University of Science and Technology, Trondheim, Norway.
Journal of Biomedical Materials Research. Part A
|June 30, 2021
Summary
Beta-cyclodextrin (β-CyD) modified alginate hydrogels enhance paclitaxel delivery for cancer therapy. These novel drug delivery systems show potential for sustained release and improved drug solubility, demonstrating cytotoxic effects on prostate cancer cells.
Area of Science:
- Biomaterials Science
- Drug Delivery
- Polymer Chemistry
Background:
- Beta-cyclodextrins (β-CyD) improve drug solubility, stability, and release profiles.
- Alginate is a natural polysaccharide suitable for hydrogel formation and drug encapsulation.
Purpose of the Study:
- To develop and characterize a novel hydrogel drug delivery system using alginate functionalized with β-CyD moieties for local paclitaxel delivery.
- To evaluate the impact of β-CyD modification on hydrogel properties, paclitaxel complexation, release kinetics, and in vitro efficacy against prostate cancer cells.
Main Methods:
- Alginate was functionalized with β-CyD moieties.
- Hydrogels were prepared and characterized for rheological and mechanical properties.
- In vitro paclitaxel release and cytotoxicity assays on PC-3 prostate cancer cells were performed.
Main Results:
- β-CyD modification reduced hydrogel mechanical properties but did not significantly alter gelation kinetics.
- β-CyD-modified alginate reduced paclitaxel crystallization and facilitated its diffusion from the gel.
- Grafted β-CyD alginate exhibited enhanced paclitaxel complexation capacity compared to free HPβ-CyD.
- Released paclitaxel and degradation products demonstrated cytotoxic effects on PC-3 cells.
Conclusions:
- Functionalized alginate with β-CyDs shows promise as a material for advanced drug delivery systems.
- The developed hydrogel system effectively delivers paclitaxel, improving its properties and demonstrating anti-cancer activity.


